Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT04420130
Other study ID # SHR-1210-HLJ-009
Secondary ID
Status Withdrawn
Phase N/A
First received
Last updated
Start date August 1, 2020
Est. completion date August 1, 2023

Study information

Verified date October 2022
Source Harbin Medical University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a a single-arm, prospective study of Camrelizumab combined with ablation and chemotherapy for patients with Pancreatic cancer liver metastasis. The main purpose of this study is to evaluate the safety and tolerability of Camrelizumab combined with ablation and chemotherapy as a treatment of Pancreatic cancer liver metastasis.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date August 1, 2023
Est. primary completion date August 1, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - Patients with liver metastasis of pancreatic cancer diagnosed by histology or cytology; - Must have CT or MRI examination in the last 3 months; - With measurable tumor lesions (spiral CT scan =10mm, meet RECIST 1.1 standard); - Expected survival time> 3 months; - The interval between the end of the patient's previous chemotherapy or adjuvant chemotherapy must be more than 6 months; - No radiation therapy (unless there is at least one measurable target lesion in the non-irradiated area); - Must score pain; - Age: 18 to 70 years old, male or female; - ECOG PS: 0-1 points; - The functions of important organs meet the following requirements: 1. Absolute neutrophil count =1.5×109/L, platelet =100×109/L, hemoglobin =9g/dL; 2. Bilirubin = 1.5 times ULN (patients drained by retrograde technique may be included); ALT and AST = 5 times ULN; 3. Creatinine <120 µmol/L, or MDRD creatinine clearance rate> 60 mL/min; - Women of childbearing age must undergo a negative pregnancy test (ßHCG) before starting treatment. Women and men of childbearing age (sexual relationships with women of childbearing age) must agree to use them effectively during treatment and 6 months after the last dose of treatment Contraceptive measures; - Signature of patient information and informed consent. Exclusion Criteria: - Women who are pregnant or nursing, or have fertility but refuse to take contraceptive measures; - During the enrollment period, a serious active infection requiring antibiotic intravenous treatment occurred; - Those who are allergic to test drugs; - Presence of =2 grade neuropathy (CTCAE 5.0); - Uncontrolled, symptomatic brain metastases or those with a history of difficult-to-control mental illness or severe intellectual or cognitive dysfunction; - Suffering from active, known or suspected autoimmune diseases (including but not limited to: uveitis, enteritis, hepatitis, pituitary inflammation, nephritis, vasculitis, hyperthyroidism, hypothyroidism and the need for bronchodilators Treatment of asthma, etc.). Subjects with hypothyroidism who only need hormone replacement therapy and skin diseases that do not require systemic treatment (such as vitiligo, psoriasis, or hair loss) can be selected; - Have been vaccinated or will be vaccinated with live vaccine within 30 days before the administration of Camrelizumab; - Congestive heart failure, uncontrolled arrhythmia, myocardial infarction, unstable angina, stroke or transient ischemic attack within 6 months; or other patients who cannot tolerate surgery; - Suffering from other malignant tumors within 5 years, except for fully treated cervical carcinoma in situ or squamous cell carcinoma of the skin, or basal cell carcinoma of the skin that has been basically controlled; - Patients who cannot comply with the trial protocol or cannot cooperate with follow-up; - The patient has already participated in another clinical trial; - People deprived of their liberty or guardianship; - Unable to receive medical supervision during the trial due to geographical, social or psychological reasons; - Patients who cannot follow the trial protocol or cannot cooperate with follow-up; - The researchers believe that it is not appropriate to participate in this experiment.

Study Design


Intervention

Drug:
Camrelizumab
Camrelizumab was administered 200mg iv every 3 weeks
Chemotherapy
The chemotherapy regimen may be a standard regimen for routine treatment of advanced pancreatic cancer.
Procedure:
Ablation
First give pancreatic cancer patients with liver metastases to ablation of liver metastases

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Yanqiao Zhang

Outcome

Type Measure Description Time frame Safety issue
Primary 6-month PFS rate 6-month progression-free survival rate From date of starting treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 6 months.
Secondary ORR Overall Response Rate From the first drug administration up to two years
Secondary DCR Disease Control Rate From the first drug administration up to two years
Secondary PFS Progression Free Survival From the first drug administration up to two years
Secondary Incidence of Treatment-Emergent Adverse Events adverse events/serious adverse events from the first drug administration to within 90 days for the last Camrelizumab combined with ablation and chemotherapy
See also
  Status Clinical Trial Phase
Completed NCT05305001 - Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Recruiting NCT05497531 - Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers N/A
Recruiting NCT04927780 - Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer Phase 3
Recruiting NCT06054984 - TCR-T Cells in the Treatment of Advanced Pancreatic Cancer Early Phase 1
Recruiting NCT05919537 - Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation Phase 1
Terminated NCT03140670 - Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy Phase 2
Terminated NCT00529113 - Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer Phase 1
Recruiting NCT05168527 - The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients Phase 2
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Recruiting NCT05391126 - GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care N/A
Terminated NCT03300921 - A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer Phase 1
Completed NCT03153410 - Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas Early Phase 1
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2
Recruiting NCT05679583 - Preoperative Stereotactic Body Radiation Therapy in Patients With Resectable Pancreatic Cancer Phase 2
Recruiting NCT04183478 - The Efficacy and Safety of K-001 in the Treatment of Advanced Pancreatic Cancer Phase 2/Phase 3
Terminated NCT03600623 - Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer Early Phase 1
Recruiting NCT04584008 - Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics N/A
Recruiting NCT05351983 - Patient-derived Organoids Drug Screen in Pancreatic Cancer N/A
Completed NCT04290364 - Early Palliative Care in Pancreatic Cancer - a Quasi-experimental Study